AP Photo/Richard DrewMark Baum thrust himself into drug-price debate last year when he offered to make a $1 version of Daraprim, the toxoplasmosis treatment that Martin Shkreli was selling for $750 a pill. Now, Baum has a new target in his sights. Called Thiola, the drug also treats a rare disease and is owned by a company that hiked its price substantially – by 2000% in 2014 –without any real justification. And, in fact, the architect of Thiola's price hike was none other than Shkreli.